Loading...
•
Jun 30, 2024
Gyre Therapeutics Q2 2024 Earnings Report
Reported second quarter 2024 financial results and provided a business update.
Key Takeaways
Gyre Therapeutics reported revenues of $25.2 million and a net income of $4.5 million for the second quarter ended June 30, 2024. The company received NMPA approval for avatrombopag maleate tablets and IND approval from NMPA to evaluate F230 for the treatment of pulmonary arterial hypertension.
Received NMPA approval of avatrombopag maleate tablets for CLD-associated thrombocytopenia.
Received IND approval from NMPA to evaluate F230 for pulmonary arterial hypertension.
U.S. IND submission for F351 in MASH-associated liver fibrosis expected in late 2024.
Phase 3 trial data readout from CHB-associated liver fibrosis in the PRC expected by early 2025.
Gyre Therapeutics
Gyre Therapeutics
Gyre Therapeutics Revenue by Segment
Gyre Therapeutics Revenue by Geographic Location
Revenue by Segment
License & Collaboration Revenue
CapyFin.comRevenue by Geographic Location
PRC Revenue
CapyFin.com Forward Guidance
Gyre anticipates that its cash resources as of June 30, 2024 will enable it to fund operations through at least 12 months following the issuance of the condensed consolidated financial statements.